Abstract
CRISPR-based target validation of 10 anticancer drugs suggests many therapies don't work as thought. The findings call into question some of the common techniques used for demonstrating a drug's on-target mechanism of action.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.